Advertisement

Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study

      Abstract

      Background

      In Europe skin melanoma (SM) survival has increased over time. The aims were to evaluate recent trends and differences between countries and regions of Europe.

      Methods

      Relative survival (RS) estimates and geographical comparisons were based on 241,485 patients aged 15 years and over with a diagnosis of invasive SM in Europe (2000–2007). Survival time trends during 1999–2007 were estimated using the period approach, for 213,101 patients. Age, gender, sub-sites and morphology subgroups were considered.

      Results

      In European patients, estimated 5-year RS was 83% (95% confidence interval, CI 83–84%). The highest values were found for patients resident in Northern (88%; 87–88%) and Central (88%; 87–88%) Europe, followed by Ireland and United Kingdom (UK) (86%; 85–86%) and Southern Europe (83%; 82–83%). The lowest survival was in Eastern Europe (74%; 74–75%). Within regions the intercountry absolute difference in percentage points of RS varied from 4% (North) to 34% (East). RS decreased markedly with patients’ age and was higher in women than men. Differences according to SM morphology and skin sub-sites also emerged. Survival has slightly increased from 1999 to 2007, with a small improvement in Northern and the most pronounced improvement in Eastern Europe.

      Discussion

      SM survival is high and still increasing in European patients. The gap between Northern and Southern and especially Eastern European countries, although still present, diminished over time. Differences in stage distribution at diagnosis may explain most of the geographical differences. However, part of the improvement in survival may be attributed to overdiagnosis from early diagnosis practices.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Erdmann F.
        • Lortet-Tieulent J.
        • Schüz J.
        • Zeeb H.
        • Greinert R.
        • Breitbart E.W.
        • et al.
        International trends in the incidence of malignant melanoma 1953–2008 – Are recent generations at higher or lower risk?.
        Int J Cancer. 2013; 132: 385-400
      1. Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, et al. European cancer observatory: cancer incidence, mortality, prevalence and survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. Available from <http://eco.iarc.fr> (accessed on 4/September/2014).

        • Wehner M.R.
        • Chren M.M.
        • Nameth D.
        • Choudhry A.
        • Gaskins M.
        • Nead K.T.
        • et al.
        International prevalence of indoor tanning: a systematic review and meta-analysis.
        JAMA Dermatol. 2014; 150: 390-400
        • Bosetti C.
        • Bertuccio P.
        • Malvezzi M.
        • Levi F.
        • Chatenoud L.
        • Negri E.
        • La Vecchia C.
        Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980.
        Ann Oncol. 2013; 24: 2657-2671
        • Sant M.
        • Capocaccia R.
        • Coleman M.P.
        • Berrino F.
        • Gatta G.
        • Micheli A.
        • et al.
        Cancer survival increases in Europe, but international differences remain wide.
        Eur J Cancer. 2001; 37: 1659-1667
        • De Angelis R.
        • Sant M.
        • Coleman M.P.
        • Francisci S.
        • Baili P.
        • Pierannunzio D.
        • et al.
        Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – A population-based study.
        Lancet Oncol. 2014; 15: 23-34
        • Balch C.M.
        • Soong S.J.
        • Atkins M.B.
        • Buzaid A.C.
        • Cascinelli N.
        • Coit D.G.
        • et al.
        An evidence-based staging system for cutaneous melanoma.
        CA Cancer J Clin. 2004; 54: 131-149
        • Cho H.
        • Mariotto A.B.
        • Schwartz L.M.
        • Luo J.
        • Woloshin S.
        When do changes in cancer survival mean progress? The insight from population incidence and mortality.
        J Natl Cancer Inst Monogr. 2014; 49: 187-197
      2. Fritz A.G. Percy C. Jack A. International Classification of Diseases for Oncology (ICD-O). 3rd ed. World Health Organization, Geneva2000
        • Rossi S.
        • Baili P.
        • Caldora M.
        • Carrani E.
        • Minicozzi P.
        • Pierannunzio D.
        • et al.
        The EUROCARE-5 study on cancer survival in Europe: database, quality checks and methods of statistical analysis.
        Eur J Cancer. 2015; 51: 2104-2119
        • Brenner H.
        • Gefeller O.
        • Hakulinen T.
        Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications.
        Eur J Cancer. 2004; 40: 326-335
        • Brenner H.
        • Hakulinen T.
        Up-to-date long-term survival curves of patients with cancer by period analysis.
        J Clin Oncol. 2002; 20: 826-832
        • Corazziari I.
        • Quinn M.
        • Capocaccia R.
        Standard cancer patient population for age standardising survival ratios.
        Eur J Cancer. 2004; 40: 2307-2316
        • Ederer F.
        • Heise H.
        Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10.
        End Results Evaluation Section, National Cancer Institute, Bethesda, MD1959
        • Pearson K.
        Mathematical contributions to the theory of evolution—III. Regression, heredity, and panmixia.
        Philos Trans R Soc Lond A. 1896; 187: 253-318
      3. SEER Stat Fact Sheets: Melanoma of the Skin. Available from: seer.cancer.govcite [cited 2015 Jul 3].

      4. Australian Government Cancer Australia. Melanoma of the skin statistics [cited 2015 July 3] Available from: <http://www.canceraustralia.gov.au>.

        • Coleman M.P.
        • Gatta G.
        • Verdecchia A.
        • Estève J.
        • Sant M.
        • Storm H.
        • et al.
        EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.
        Annal Oncol. 2003; 14: v128-v149
        • de Vries E.
        • Boniol M.
        • Doré J.F.
        • Coebergh J.W.
        • EUROCARE working group
        Lower incidence rates but thicker melanomas in Eastern Europe before 1992: a comparison with Western Europe.
        Eur J Cancer. 2004; 40: 1045-1052
        • Sant M.
        • Allemani C.
        • Santaquilani M.
        • Knijn A.
        • Marchesi F.
        • Capocaccia R.
        • et al.
        EUROCARE- 4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary.
        Eur J Cancer. 2009; 45: 931-991
        • Geller A.C.
        • Swetter S.M.
        • Oliveria S.
        • Dusza S.
        • Halpern A.C.
        Reducing mortality in individuals at high risk for advanced melanoma through education and screening.
        J Am Acad Dermatol. 2011; 65: s87-s94
        • Mayer J.E.
        • Swetter S.M.
        • Fu T.
        • Geller A.C.
        Screening, early detection, education, and trends for melanoma: Current status (2007–2013) and future directions: Part II. Screening, education, and future directions.
        J Am Acad Dermatol. 2014; 71 (e1–e611.e10): 611
        • Schneider J.S.
        • Moore 2nd, D.H.
        • Mendelsohn M.L.
        Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996.
        J Am Acad Dermatol. 2008; 58: 741-749
        • Aitken J.F.
        • Elwood J.M.
        • Lowe J.B.
        • Firman D.W.
        • Balanda K.P.
        • Ring I.T.
        A randomised trial of population screening for melanoma.
        J Med Screen. 2002; 9: 33-37
        • Swetter S.M.
        • Pollitt R.A.
        • Johnson T.M.
        • Brooks D.R.
        • Geller A.C.
        Behavioral determinants of successful early melanoma detection: role of self and physician skin examination.
        Cancer. 2012; 118: 3725-3734
        • Katalinic A.
        • Waldmann A.
        • Weinstock M.A.
        • Geller A.C.
        • Eisemann N.
        • Greinert R.
        • et al.
        Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening.
        Cancer. 2012; 118: 5395-5402
        • Aitken J.F.
        • Elwood M.
        • Baade P.D.
        • Youl P.
        • English D.
        Clinical whole-body skin examination reduces the incidence of thick melanomas.
        Int J Cancer. 2010; 126: 450-458
        • Glusac E.J.
        The melanoma ‘epidemic’: lessons from prostate cancer.
        J Cutan Pathol. 2012; 39: 17-20
        • Curiel-Lewandrowski C.
        • Kim C.C.
        • Swetter S.M.
        • Chen S.C.
        • Halpern A.C.
        • Kirkwood J.M.
        • et al.
        Melanoma Prevention Working Group—Pigmented Skin Lesion Sub-Committee Survival is not the only valuable end point in melanoma screening.
        J Invest Dermatol. 2012; 132: 1332-1337
        • Welch H.G.
        • Woloshin S.
        • Schwartz L.M.
        Skin biopsy rates and incidence of melanoma: population based ecological study.
        BMJ. 2005; 331: 481
        • Stefansson H.
        • Tryggvadottir L.
        • Olafsdottir E.J.
        • Mooney E.
        • Olafsson J.H.
        • Sigurgeirsson B.
        • et al.
        Cutaneous melanoma in Iceland: changing Breslow’s tumour thickness.
        J Eur Acad Dermatol Venereol. 2015; 29: 346-352
        • Welch H.G.
        • Black W.C.
        Overdiagnosis in cancer.
        J Natl Cancer Inst. 2010; 102: 605-613
        • Eriksson H.
        • Lyth J.
        • Månsson-Brahme E.
        • Frohm-Nilsson M.
        • Ingvar C.
        • Lindholm C.
        • et al.
        Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
        Eur J Cancer. 2013; 49: 2705-2716
        • Jiang A.J.
        • Rambhatla P.V.
        • Eide M.J.
        Socioeconomic and lifestyle factors and melanoma: a systematic review.
        Br J Dermatol. 2015; 172: 885-915
        • Munro A.J.
        Comparative cancer survival in European countries.
        Br Med Bull. 2014; 110: 5-22
      5. Paolo Baili, Francesca Di Salvo, Rafael Marcos-Gragera, Sabine Siesling, Sandra Mallone, Mariano Santaquilani, et al. Survival for all cancer patients diagnosed between 1999 and 2007 in Europe: results of EUROCARE-5, a population-based study. Eur J Cancer 2015;51:2120–9.

        • Eggermont A.M.
        • Spatz A.
        • Robert C.
        Cutaneous melanoma.
        Lancet. 2014; 383: 816-827
        • Sant M.
        • Aareleid T.
        • Berrino F.
        • Bielska Lasota M.
        • Carli P.M.
        • Faivre J.
        • et al.
        EUROCARE-3: survival of cancer patients diagnosed 1990–94-results and commentary.
        Ann Oncol. 2003; 14: v61-v118
        • Joosse A.
        • de Vries E.
        • Eckel R.
        • Nijsten T.
        • Eggermont A.M.
        • HÖlzel D.
        • et al.
        Gender differences in melanoma survival: female patients have a decreased risk of metastasis.
        J Invest Dermatol. 2011; 131: 719-726
        • Bay C.
        • Kejs A.M.
        • Storm H.H.
        • Engholm G.
        Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989–2011.
        Cancer Epidemiol. 2015; 39: 1-7
        • De Angelis R.
        • Francisci S.
        • Baili P.
        • Marchesi F.
        • Roazzi P.
        • Belot A.
        • et al.
        The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis.
        Eur J Cancer. 2009; 45: 909-930
        • Gatta G.
        • Mallone S.
        • van der Zwan J.M.
        • Trama A.
        • Siesling S.
        • Capocaccia R.
        • et al.
        Cancer prevalence estimates in Europe at the beginning of 2000.
        Ann Oncol. 2013; 24: 1660-1666
        • Karim-Kos H.E.
        • Kiemeney L.A.L.M.
        • Louwman M.W.J.
        • Coebergh J.W.W.
        • de Vries E.
        Progress against cancer in the Netherlands since the late 1980s: an epidemiological evaluation.
        Int J Cancer. 2012; 130: 2981-2989
      6. IARC, WHO. European code against cancer - Fourth edition, 14 October 2014. Available at: <http://cancer-code-europe.iarc.fr>.